CXCL13 as a Biomarker: Background and Utility in Multiple Sclerosis

Andrew R. Pachner; Steven Pike; Andrew D. Smith; Francesca Gilli

doi:10.3390/biom14121541

Biomolecules (Nov 2024)

CXCL13 as a Biomarker: Background and Utility in Multiple Sclerosis

Andrew R. Pachner,
Steven Pike,
Andrew D. Smith,
Francesca Gilli

Affiliations

Andrew R. Pachner: Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA
Steven Pike: Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA
Andrew D. Smith: Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA
Francesca Gilli: Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA

DOI: https://doi.org/10.3390/biom14121541
Journal volume & issue: Vol. 14, no. 12
p. 1541

Abstract

Read online

CXCL13 is a chemokine which is upregulated within the CNS in multiple sclerosis, Lyme neuroborreliosis, and other inflammatory diseases and is increasingly clinically useful as a biomarker. This review provides background for understanding its function in the immune system and its relationship to ectopic lymphoid follicles. Also reviewed are its utility in multiple sclerosis and Lyme neuroborreliosis and potential problems in its measurement. CXCL13 has the potential to be an exceptionally useful biomarker in a range of inflammatory diseases.

Published in Biomolecules

ISSN: 2218-273X (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Microbiology
Website: https://www.mdpi.com/journal/biomolecules

About the journal

Abstract

Keywords